Evidence map›Paper›PMID 33242537›Full record

ReviewAdvanced drug delivery reviews2021

Automation and data-driven design of polymer therapeutics.

Rahul Upadhya, Shashank Kosuri, Matthew Tamasi, Travis A Meyer, Supriya Atta, Michael A Webb, Adam J Gormley

Abstract readReview
In one paragraph

Review in Advanced drug delivery reviews, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Machine Learning in Polymer Research.Advanced materials (Deerfield Beach, Fla.) · 2025
    Review
  9. Article
  10. Review
  11. Mapping Biomaterial Complexity by Machine Learning.Tissue engineering. Part A · 2024
    Review
  12. Self-Reporting Therapeutic Protein Nanoparticles.ACS applied materials & interfaces · 2024
    Article
  13. Review
  14. Polymer designChemical science · 2024
    Article
  15. Article
  16. Efficient ocular delivery of siRNAInternational journal of pharmaceutics: X · 2023
    Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Rahul UpadhyaRutgers, The State University of New Jersey, USA.
Shashank KosuriRutgers, The State University of New Jersey, USA.
Matthew TamasiRutgers, The State University of New Jersey, USA.
Travis A MeyerRutgers, The State University of New Jersey, USA.
Supriya AttaRutgers, The State University of New Jersey, USA.
Michael A WebbDepartment of Chemical and Biological Engineering, Princeton University, Princeton, NJ 08540, USA.
Adam J GormleyRutgers, The State University of New Jersey, USA. Electronic address: Adam.Gormley@rutgers.edu.

Funding

X-RAY STRUCTURE OF RIFM PROTEIN FROM THE BIOSYNTHESIS PATHWAY OF THE ANSAMYCIN AP41RR012408 · NCRR · BROOKHAVEN SCIENCE ASSOC-BROOKHAVEN LAB · PI SWEET, ROBERT M · 1998 to 2011
$32.2M
IRACDA at Rutgers: INSPIRE Postdoctoral Training ProgramK12GM093854 · NIGMS · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI Detlev Boison, Gary A. Brewer · 2010 to 2026
$14.7M
UMDNJ TRAINING GRANT IN BIOTECHNOLOGYT32GM008339 · NIGMS · RUTGERS THE ST UNIV OF NJ NEW BRUNSWICK · PI YARMUSH, MARTIN L · 1989 to 2019
$6.1M
Rutgers Biotechnology Training ProgramT32GM135141 · NIGMS · RUTGERS, THE STATE UNIV OF N.J. · PI ANN M. STOCK, Martin L Yarmush · 2020 to 2026
$3.5M
Tuning multivalency for optimized ligand presentationR35GM138296 · NIGMS · RUTGERS, THE STATE UNIV OF N.J. · PI GORMLEY, ADAM JOSEPH · 2020 to 2024
$2.3M
NCRR NIH HHS P41 RR012408NIGMS NIH HHS K12 GM093854NIGMS NIH HHS R35 GM138296NIGMS NIH HHS T32 GM008339NIGMS NIH HHS T32 GM135141
6 · The paper itself

Abstract

Polymers are uniquely suited for drug delivery and biomaterial applications due to tunable structural parameters such as length, composition, architecture, and valency. To facilitate designs, researchers may explore combinatorial libraries in a high throughput fashion to correlate structure to function. However, traditional polymerization reactions including controlled living radical polymerization (CLRP) and ring-opening polymerization (ROP) require inert reaction conditions and extensive expertise to implement. With the advent of air-tolerance and automation, several polymerization techniques are now compatible with well plates and can be carried out at the benchtop, making high throughput synthesis and high throughput screening (HTS) possible. To avoid HTS pitfalls often described as "fishing expeditions," it is crucial to employ intelligent and big data approaches to maximize experimental efficiency. This is where the disruptive technologies of machine learning (ML) and artificial intelligence (AI) will likely play a role. In fact, ML and AI are already impacting small molecule drug discovery and showing signs of emerging in drug delivery. In this review, we present state-of-the-art research in drug delivery, gene delivery, antimicrobial polymers, and bioactive polymers alongside data-driven developments in drug design and organic synthesis. From this insight, important lessons are revealed for the polymer therapeutics community including the value of a closed loop design-build-test-learn workflow. This is an exciting time as researchers will gain the ability to fully explore the polymer structural landscape and establish quantitative structure-property relationships (QSPRs) with biological significance.

Indexed as

AutomationDrug DesignAnimalsHigh-Throughput Screening AssaysHumansPolymersPolymersArtificial intelligenceAutomationDrug deliveryGene deliveryHigh throughput screeningMachine learningPolymer chemistry

Identifiers

PMID33242537
PMCPMC8127395

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.